Sonoma Pharmaceuticals Inc. (SNOA)
NASDAQ: SNOAHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SNOA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.55M
- EPS (TTM)
- -$1.22
- Dividend yield
- None
- 52-week range
- 0.85 – 4.30
- Day range
- 1.14 – 1.20
- Volume / Avg
- 88.62K / 107.65K
- Beta
- —
- Shares outstanding
- 4.79M
- Next earnings
- Nov 3, 2026
52-week range
SNOA stock today
Shares of Sonoma Pharmaceuticals (SNOA) finished lower on Oct 8 at $1.16, a drop of 4.92% or $0.06 per share, versus the S&P 500's 0.47% decline. Shares are 73.0% below their 52-week high of $4.30 and 36.5% above the 52-week low of $0.85, near the bottom of the past year's range. Sonoma Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.22), so its P/E ratio is not meaningful.
Sonoma Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Sonoma Pharmaceuticals
Company profileSonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ms. Amy M. Trombly Esq., J.D.
- Headquarters
- Boulder, CO
- Employees
- 10
- IPO year
- 2007
- Website
- sonomapharma.com
Earnings
Earnings history- Next report
- Nov 3, 2026
Sonoma Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GELSGelteq Limited | 0.5488 | -1.98% | $5.88M | vs SNOA |
| RDHLRedhill Biopharma Ltd. ADR | 0.578 | +21.94% | $5.14M | vs SNOA |
| AKANAkanda Corp. | 1.78 | -7.77% | $4.70M | vs SNOA |
| YCBDcbdMD Inc. | 0.3948 | -3.00% | $4.42M | vs SNOA |
| INMInMed Pharmaceuticals Inc. | 1.33 | 0.00% | $7.31M | vs SNOA |
| PRFXPRF Technologies Ltd. | 0.8587 | -2.16% | $3.00M | vs SNOA |
| IMCCIM Cannabis Corp. | 1.72 | -9.47% | $2.83M | vs SNOA |
| APUSApimeds Pharmaceuticals US Inc. | 5.51 | -21.84% | $8.32M | vs SNOA |
Indexes, lists and sector
Appears in lists
Sonoma Pharmaceuticals stock FAQ
What is Sonoma Pharmaceuticals's stock price today?
SNOA last traded at $1.16 as of Oct 8, 4:00 PM EDT, down 4.92% on the day. Prices are delayed at least 15 minutes.
When is Sonoma Pharmaceuticals's next earnings date?
Sonoma Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026.
Who is Sonoma Pharmaceuticals's CEO?
Ms. Amy M. Trombly Esq., J.D. is the chief executive officer of Sonoma Pharmaceuticals Inc., which has about 10 employees.
What is the SNOA 52-week high?
The 52-week high for SNOA is $4.30 and the 52-week low is $0.85. The stock is currently 73.0% below its high.